Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Clearmind Medicine Inc.
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
21 mars 2025 09h28 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
19 mars 2025 07h35 HE
|
Clearmind Medicine Inc.
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
18 mars 2025 07h32 HE
|
Clearmind Medicine Inc.
Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),...
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
10 mars 2025 07h27 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
04 févr. 2025 08h35 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Announces Shareholders Meeting Results
07 janv. 2025 09h28 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
06 janv. 2025 08h15 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
02 janv. 2025 07h45 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
26 déc. 2024 06h59 HE
|
Clearmind Medicine Inc.
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
24 déc. 2024 06h55 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...